project id: TCGA-TGCT; case submitter id: TCGA-2G-AAGV; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.81; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.99; rna integrity number: 7.0; age at index: 23; days to birth: -8612; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1979; age at diagnosis: 8612; ajcc clinical m: M0; ajcc clinical n: N1; ajcc clinical stage: Stage IIA; ajcc clinical t: T1; ajcc pathologic m: M0; ajcc pathologic n: NX; ajcc pathologic t: T1; ajcc staging system edition: 5th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 4527.0; icd 10 code: C62.90; igcccg stage: Good Prognosis; last known disease status: not reported; morphology: 9080/0; primary diagnosis: Teratoma, benign; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Testis, NOS; synchronous malignancy: No; tissue or organ of origin: Testis, NOS; tumor grade: Not Reported; year of diagnosis: 2002; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 4219; days to sample procurement: 0; initial weight: 300.0; portion submitter id: TCGA-2G-AAGV-01A-11; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 80.0;